Stockscreener 앱 받기
12.79
2.14%
-0.28
전일 마감가:
$13.07
열려 있는:
$13.08
하루 거래량:
671.62K
Relative Volume:
0.62
시가총액:
$581.56M
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-15.41
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
-5.85%
1개월 성능:
-17.75%
6개월 성능:
+178.65%
1년 성능:
+115.32%
1일 변동 폭
$12.67
$13.42
1주일 범위
$11.75
$13.90
52주 변동 폭
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
12.79 | 581.56M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - Defense World
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition - AOL
Capricor at Leerink’s Conference: Strategic Moves in Cell Therapy By Investing.com - Investing.com UK
Rare Disease Biotech Capricor Therapeutics Announces Critical Year-End Earnings Date - StockTitan
Capricor Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025 - Nasdaq
Capricor Therapeutics to Present Fourth Quarter and Full - GlobeNewswire
Capricor Therapeutics receives FDA acceptance of BLA for deramiocel - TipRanks
Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA - Marketscreener.com
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment - Lelezard
Capricor's DMD Treatment Receives FDA Priority Review Status - StockTitan
Rhumbline Advisers Has $636,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Capricor Therapeutics to Provide Corporate Update and Participate in Investor Meetings at Leerink’s Global Healthcare Conference 2025 - Nasdaq
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire
Can Capricor's DMD Treatment Breakthrough Change Rare Disease Treatment? Key Updates Coming - StockTitan
New York State Common Retirement Fund Raises Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory - Insider Monkey
Capricor Therapeutics call volume above normal and directionally bullish - TipRanks
Capricor jumps on FDA priority review for lead drug - MSN
Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy - Asianet Newsable
How To Trade (CAPR) - Stock Traders Daily
H.C. Wainwright maintains Buy on Capricor stock with $77 target By Investing.com - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Given “Buy” Rating at HC Wainwright - Defense World
Traders Buy Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Capricor: Further Value Unlocked With Priority Review Of Deramiocel (NASDAQ:CAPR) - Seeking Alpha
CAPR underperforms with a -11.12 decrease in share price - US Post News
Capricor Therapeutics Shares Rise on FDA Priority Review -March 04, 2025 at 10:42 am EST - Marketscreener.com
Capricor, Wave Life Sciences, EVgo - TradingView
Capricor Therapeutics stock rises on FDA priority review By Investing.com - Investing.com Canada
Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment - Marketscreener.com
Capricor Therapeutics’ Deramiocel Receives FDA Priority Review - TipRanks
Capricor Therapeutics Announces FDA Acceptance and Priority - GlobeNewswire
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy - The Manila Times
Capricor stock rises as FDA reviews DMD drug (CAPR:NASDAQ) - Seeking Alpha
FDA reviews Capricor’s DMD cardiomyopathy therapy By Investing.com - Investing.com UK
First-Ever DMD Cardiomyopathy Treatment Advances: FDA Fast-Tracks Capricor's Groundbreaking Therapy - StockTitan
Capricor Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 8.4%Time to Buy? - MarketBeat
Capricor Therapeutics Inc [CAPR] stock for 14,999,998 USD was bought by Nippon Shinyaku Co Ltd - Knox Daily
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 4.8%Should You Sell? - MarketBeat
Capricor Therapeutics (CAPR) Expected to Announce Earnings on Thursday - Defense World
Black Diamond Financial LLC Acquires New Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Is Capricor Therapeutics, Inc. (CAPR) the Best Small-Cap Growth Stock to Buy Now? - Insider Monkey
10 Best Small-Cap Growth Stocks to Buy Now - Insider Monkey
Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data (NASDAQ:CAPR) - Seeking Alpha
Trading (CAPR) With Integrated Risk Controls - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.9%Time to Sell? - MarketBeat
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.9% – Time to Sell? - Defense World
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50 - Defense World
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):